Lv1
10 积分 2021-08-22 加入
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
3个月前
已完结
“Recovery” in bipolar disorder: How can service users be supported through a self-management intervention? A qualitative focus group study
3个月前
已完结
Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities
4个月前
已完结
Anti-IL-23 Phase II Data for Psoriasis: A Review
4个月前
已关闭
Deucravacitinib: is there still a place or a need for a new oral agent?
6个月前
已完结
Disease modification in inflammatory skin disorders: opportunities and challenges
7个月前
已完结
Disease modification in inflammatory skin disorders: opportunities and challenges
7个月前
已完结
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
9个月前
已关闭
Negative impact of comorbidities on all-cause mortality of psoriasis patients is partially alleviated by biologic treatment: A real-world, case-control study
9个月前
已完结
Negative impact of comorbidities on all-cause mortality of psoriasis patients is partially alleviated by biologic treatment: A real-world, case-control study
9个月前
已完结
皖公网安备34019202002308
